Literature DB >> 27979032

Prevalence and outcome of thrombotic and embolic complications in adults after Fontan operation.

Alexander C Egbe1, Heidi M Connolly2, Talha Niaz3, Vidhushei Yogeswaran4, Nathaniel W Taggart5, Muhammad Y Qureshi5, Joseph T Poterucha5, Arooj Razzaq Khan2, David J Driscoll5.   

Abstract

There are limited studies of thrombotic and embolic complications (TEC) in the adult Fontan population. The purpose of the study was to determine the prevalence, risk factors, and outcomes of TECs in this population.
METHODS: Retrospective review of adults with a previous Fontan operation, with follow-up at Mayo Clinic, 1994-2014. Systemic TEC was defined as intracardiac thrombus, ischemic stroke, or systemic arterial embolus. Nonsystemic TEC was defined as Fontan conduit/right atrial thrombus or pulmonary embolus.
RESULTS: We identified 387 patients with a mean (SD) age of 28 (7) years and a mean follow-up of 8 (2) years. An atriopulmonary connection (APC) was done for 286 patients (74%). Atrial arrhythmias were present in 278 (72%). There were 121 TECs (systemic n=36, nonsystemic n=85) in 98 patients (25%). Risk factors for systemic TEC were atrial arrhythmia (hazard ratio 2.28, P=.001) and APC (hazard ratio 1.98, P=.02); nonsystemic TEC also had similar risk factors. All 98 patients received warfarin. Warfarin was discontinued in 10 of 98 because of bleeding, and 8 of these 10 subsequently had a second TEC. Among the 82 patients who had follow-up imaging, 16 (20%) had resolution of thrombus. In total, 24 of 98 patients had a second TEC, most of whom had inadequate anticoagulation.
CONCLUSIONS: Thrombotic and embolic complication was not uncommon; risk factors for TEC were APC and atrial arrhythmias. Most patients were treated successfully with warfarin alone. A second TEC occurred in most patients whose anticoagulation was discontinued because of bleeding events.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27979032     DOI: 10.1016/j.ahj.2016.09.014

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  13 in total

Review 1.  Management of acute heart failure in adult patients with congenital heart disease.

Authors:  Alexander Van De Bruaene; Lukas Meier; Walter Droogne; Pieter De Meester; Els Troost; Marc Gewillig; Werner Budts
Journal:  Heart Fail Rev       Date:  2018-01       Impact factor: 4.214

Review 2.  Thromboembolic complications in adult congenital heart disease: the knowns and the unknowns.

Authors:  Magalie Ladouceur; Clément Karsenty; Victor Waldmann; Barbara Mulder; Sébastien Hascoet
Journal:  Clin Res Cardiol       Date:  2020-10-09       Impact factor: 5.460

Review 3.  Anesthetic Management in Adults with Congenital Heart Disease.

Authors:  Jon S Andrews; Nazish K Hashmi
Journal:  Curr Cardiol Rep       Date:  2022-01-26       Impact factor: 2.931

4.  A multinational observational investigation of illness perceptions and quality of life among patients with a Fontan circulation.

Authors:  Christina E Holbein; Nicholas D Fogleman; Kevin Hommel; Silke Apers; Jessica Rassart; Philip Moons; Koen Luyckx; Maayke A Sluman; Junko Enomoto; Bengt Johansson; Hsiao-Ling Yang; Mikael Dellborg; Raghavan Subramanyan; Jamie L Jackson; Werner Budts; Adrienne H Kovacs; Stacey Morrison; Martha Tomlin; Kathy Gosney; Alexandra Soufi; Katrine Eriksen; Corina Thomet; Malin Berghammer; Luis Alday; Edward Callus; Susan M Fernandes; Maryanne Caruana; Samuel Menahem; Stephen C Cook; Gwen R Rempel; Kamila White; Paul Khairy; Shelby Kutty; Gruschen Veldtman
Journal:  Congenit Heart Dis       Date:  2018-01-03       Impact factor: 2.007

Review 5.  Where Is the "Optimal" Fontan Hemodynamics?

Authors:  Hideo Ohuchi
Journal:  Korean Circ J       Date:  2017-09-18       Impact factor: 3.243

6.  Outcomes of Anticoagulation Therapy in Adults With Tetralogy of Fallot.

Authors:  Alexander C Egbe; William R Miranda; Naser M Ammash; Venkata R Missula; Raja Jadav; Maria Najam; Srikanth Kothapalli; Heidi M Connolly
Journal:  J Am Heart Assoc       Date:  2019-03-05       Impact factor: 5.501

7.  Non-vitamin K antagonist oral anticoagulants in adults with a Fontan circulation: are they safe.

Authors:  Hayang Yang; Gruschen R Veldtman; Berto J Bouma; Werner Budts; Koichiro Niwa; Folkert Meijboom; Giancarlo Scognamiglio; Alexander Chima Egbe; Markus Schwerzmann; Craig Broberg; Marielle Morissens; Jonathan Buber; Shane Tsai; Ioannis Polyzois; Martijn C Post; Matthias Greutmann; Arie Van Dijk; Barbara Jm Mulder; Jamil Aboulhosn
Journal:  Open Heart       Date:  2019-06-03

8.  Fontan Circulation of the Next Generation: Why It's Necessary, What it Might Look Like.

Authors:  Shelby Kutty; Marshall L Jacobs; W Reid Thompson; David A Danford
Journal:  J Am Heart Assoc       Date:  2019-12-19       Impact factor: 5.501

Review 9.  State of the art of the Fontan strategy for treatment of univentricular heart disease.

Authors:  Jelle P G van der Ven; Eva van den Bosch; Ad J C C Bogers; Willem A Helbing
Journal:  F1000Res       Date:  2018-06-27

10.  Percutaneous coronary intervention following Fontan procedure.

Authors:  Ahmed Subahi; Thomas Forbes; Omar E Ali
Journal:  Int J Cardiol Heart Vasc       Date:  2020-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.